Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01569282
Other study ID # Double bypass vs Stent
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date October 2011
Est. completion date October 31, 2015

Study information

Verified date March 2019
Source Göteborg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Double bypass (hepaticojejunostomy + gastrojejunostomy) is compared to stent strategy in patients planned for curative pancreatic resection in whom peroperative findings makes resection impossible.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 31, 2015
Est. primary completion date April 30, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

1. Preoperatively

- Patients with stent treated tumor in the pancreatic head or periampullary planned for pancreaticoduodenectomy

- The patient jaundice should have worn off and there should be no signs of duodenal obstruction

- The patient has given informed consent after verbal and written information in accordance with approved ethics application

- The patient has no anatomical conditions making endoscopic therapy impossible such as previous Billroth II or Gastric Bypass.

2. Intraoperatively

- Peroperative findings of of carcinomatosis, metastases or local irresectability who oppose radical surgery

- Surgical double bypass should be technically feasible

- The patient has given informed consent after verbal and written information in accordance with approved ethics application

Exclusion Criteria:

- Peroperative signs of dysfunction on biliary stent

- Peroperative findings of gastric outlet obstruction

- Surgical double bypass not technically feasible

Study Design


Intervention

Procedure:
Hepaticojejunostomy and gastroenterostomy
Standard surgical techniques
Stent strategy
Biliary and/or enteral stents on demand

Locations

Country Name City State
Sweden Department of Surgery, Sahlgrenska University Hospital Gothenburg
Sweden Department of surgery, University Hospital Linköping
Sweden Department of Surgery, Skane University Hospital Lund
Sweden Department of Surgery, University Hospital Örebro
Sweden Gastro Center Surgery, Karolinska University Hospital Stockholm
Sweden Department of Surgery, University Hospital Umeå

Sponsors (1)

Lead Sponsor Collaborator
Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Morbidity Initial morbidity in association to the laparotomy using the Clavien-Dindo Classification. Day 1-30 after randomization
Secondary Quality of life Using the EORTC:s QLQ-C30 and QLQ-PAN26 questionaries Preop, 1 month postop and every third month
Secondary Numbers of readmissions to hospital Up to two years after the laparotomy
Secondary The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions The numbers of surgical, radiological or endoscopical interventions due to jaundice or gastric outlet obstruction from date of randomization until the date of death from any cause, whichever came first, assessed up to 24 months" Up to 24 months after the randomization
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study